Therapeutic interventions of cancers using intrinsically disordered proteins as drug targets: C-myc as model system

Cancer Informatics

Volumn 16, Issue , 2017, Pages

  Kumar, Deepak ^a   Sharma, Nitin ^a   Giri, Rajanish ^a  

^a INDIAN INSTITUTE OF TECHNOLOGY MANDI   (India)

Author keywords

And molecular recognition elements; Conformational ensembles; Intrinsically disordered proteins; Therapeutics and drug development; Transcription factors

Indexed keywords

INTRINSICALLY DISORDERED PROTEIN; MYC PROTEIN; PROTEIN INHIBITOR; TRANSCRIPTION FACTOR;

DRUG TARGETING; GENE MUTATION; HUMAN; MALIGNANT NEOPLASM; NONHUMAN; PROTEIN BINDING; PROTEIN DOMAIN; PROTEIN FOLDING; PROTEIN PROTEIN INTERACTION; PROTEIN TARGETING; REVIEW; TRANSCRIPTION REGULATION;

EID: 85016150522     PISSN: None     EISSN: 11769351     Source Type: Journal    
DOI: 10.1177/1176935117699408     Document Type: Review

References (62)

1. Uversky VN. Functional roles of transiently and intrinsically disordered regions within proteins. FEBS J. 2015;282:1182–1189.
2. Van Der Lee R, Buljan M, Lang B, et al. Classification of intrinsically disordered regions and proteins, Chem Rev. 2014;114:6589–6631.
3. Chothia C, Lesk AM. The relation between the divergence of sequence and structure in proteins. EMBO J. 1986;5:823–6.
4. Oldfield CJ, Dunker AK. Intrinsically disordered proteins and intrinsically disordered protein regions. Annu Rev Biochem. 2014;83:553–584.
5. Jirgensons B. Classification of proteins according to conformation: Die Makromol. Chemie 1966;91:74–86.
6. Forman-Kay JD, Mittag T. From sequence and forces to structure, function, and evolution of intrinsically disordered proteins. Structure. 2013;21:1492–1499.
7. Giri R, Kumar D, Sharma N, Uversky VN. Intrinsically disordered side of the Zika virus proteome. Front Cell Infect Microbiol. 2016;6:144.
8. Dunker AK, Oldfield CJ, Meng J, et al. The unfoldomics decade: an update on intrinsically disordered proteins. BMC Genomics. 2008;9:S1.
9. Dunker AK, Silman I, Uversky VN, Sussman JL. Function and structure of inherently disordered proteins. Curr Opin Struct Biol. 2008;18:756–764.
10. Romero P, Obradovic Z, Li X, Garner EC, Brown CJ, Dunker AK. Sequence complexity of disordered protein. Proteins. 2001;42:38–48.
11. Habchi J, Tompa P, Longhi S, Uversky VN. Introducing protein intrinsic disorder. Chem Rev. 2014;114:6561–6588.
12. Xue B, Dunbrack RL, Williams RW, Dunker AK, Uversky VN. PONDR-FIT: a meta-predictor of intrinsically disordered amino acids. Biochim Biophys Acta. 2010;1804:996–1010.
13. Linding R, Russell RB, Neduva V, Gibson TJ. GlobPlot: exploring protein sequences for globularity and disorder. Nucleic Acids Res. 2003;31:3701–3708.
14. Ward JJ, Sodhi JS, McGuffin LJ, Buxton BF, Jones DT. Prediction and functional analysis of native disorder in proteins from the three kingdoms of life. J Mol Biol. 2004;337:635–645.
15. Linding R, Jensen LJ, Diella F, Bork P, Gibson TJ, Russell RB. Protein disorder prediction: implications for structural proteomics. Structure. 2003;11: 1453–1459.
16. Chen JW, Romero P, Uversky VN, Dunker AK. Conservation of intrinsic disorder in protein domains and families: I. A database of conserved predicted disordered regions. J Proteome Res. 2006;5:879–887.
17. Cheng Y, LeGall T, Oldfield CJ, et al. Rational drug design via intrinsically disordered protein. Trends Biotechnol. 2006;24:435–442.
18. Uversky VN, Dunker AK. Understanding protein non-folding. Biochim Biophys Acta. 2010;1804:1231–1264.
19. Tompa P, Fuxreiter M. Fuzzy complexes: polymorphism and structural disorder in protein-protein interactions. Trends Biochem Sci. 2008;33:2–8.
20. Dogan J, Mu X, Engstrom A, et al. The transition state structure for coupled binding and folding of disordered protein domains. Sci Rep. 2013;3:6573–6582.
21. Toto A, Camilloni C, Giri R, et al. Molecular recognition by templated folding of an intrinsically disordered protein. Sci Rep. 2016;6:21994.
22. Uversky VN. Unusual biophysics of intrinsically disordered proteins. Biochim Biophys Acta. 2013;1834:932–951.
23. Brunori M, Gianni S, Giri R, Morrone A, Travaglini-Allocatelli C. Morphogenesis of a protein: folding pathways and the energy landscape. Biochem Soc Trans. 2012;40:429–432.
24. Gibbs EB, Showalter SA. Quantitative biophysical characterization of intrinsically disordered proteins. Biochemistry. 2015;54:1314–1326.
25. Kosol S, Contreras-Martos S, Cedeno C, Tompa P. Structural characterization of intrinsically disordered proteins by NMR spectroscopy. Molecules. 2013;18:10802–10828.
26. Ferreon ACM, Ferreon JC, Wright PE, Deniz AA. Modulation of allostery by protein intrinsic disorder. Nature. 2013;498:390–394.
27. Jemth P, Mu X, Engstrom A, Dogan J. A frustrated binding interface for intrinsically disordered proteins. J Biol Chem. 2014;289:5528–5533.
28. Huang Y, Liu Z. Kinetic advantage of intrinsically disordered proteins in coupled folding-binding process: a critical assessment of the ‘fly-casting’ mechanism. J Mol Biol. 2009;393:1143–1159.
29. Giri R, Morrone A, Toto A, Brunori M, Gianni S. Structure of the transition state for the binding of c-Myb and KIX highlights an unexpected order for a disordered system. Proc Natl Acad Sci U S A. 2013;110:14942–14947.
30. Toto A, Giri R, Brunori M, Gianni S. The mechanism of binding of the KIX domain to the mixed lineage leukemia protein and its allosteric role in the recognition of c-Myb. Protein Sci. 2014;23:962–969.
31. Sammak S, Zinzalla G. Targeting protein-protein interactions (PPIs) of transcription factors: challenges of intrinsically disordered proteins (IDPs) and regions (IDRs). Prog Biophys Mol Biol. 2015;119:41–46.
32. Dunker AK, Uversky VN. Drugs for ‘protein clouds’: targeting intrinsically disordered transcription factors. Curr Opin Pharmacol. 2010;10:782–788.
33. Uversky VN, Dave V, Iakoucheva LM, et al. Pathological unfoldomics of uncontrolled chaos: intrinsically disordered proteins and human diseases. Chem Rev. 2014;114:6844–6879.
34. Eilers M, Eisenman RN. Myc’s broad reach. Genes Dev. 2008;22:2755–2766.
35. Luscher B, Vervoorts J. Regulation of gene transcription by the oncoprotein Myc. Gene. 2012;494:145–160.
36. Yan C, Higgins PJ. Drugging the undruggable: transcription therapy for cancer. Biochim Biophys Acta. 2013;1835:76–85.
37. Buganim Y, Faddah DA, Jaenisch R. Mechanisms and models of somatic cell reprogramming. Nat Rev Genet. 2013;14:427–439.
38. Mahani A, Henriksson J, Wright APH. Origins of Myc proteins – using intrinsic protein disorder to trace distant relatives. PLoS ONE. 2013;8:e75057.
39. Nilsson J, Grahn M, Wright AP, et al. Proteome-wide evidence for enhanced positive Darwinian selection within intrinsically disordered regions in proteins. Genome Biol. 2011;12:R65.
40. Xue B, Oldfield CJ, Van Y-Y, Dunker AK, Uversky VN. Protein intrinsic disorder and induced pluripotent stem cells. Mol Biosyst. 2012;8:134–150.
41. Dinkel H, Michael S, Weatheritt RJ, et al. ELM – the database of eukaryotic linear motifs. Nucleic Acids Res. 2012;40:D242–D251.
42. Cole MD, McMahon SB. The Myc oncoprotein: a critical evaluation of transactivation and target gene regulation. Oncogene. 1999;18:2916–2924.
43. Fladvad M, Zhou K, Moshref A, Pursglove S, Safsten P, Sunnerhagen M. N and C-terminal sub-regions in the c-Myc transactivation region and their joint role in creating versatility in folding and binding. J Mol Biol. 2005;346:175–189.
44. Iakoucheva LM, Brown CJ, Lawson JD, Obradović Z, Dunker AK. Intrinsic disorder in cell-signaling and cancer-associated proteins. J Mol Biol. 2002;323:573–584.
45. Adhikary S, Eilers M. Transcriptional regulation and transformation by Myc proteins. Nat Rev Mol Cell Biol. 2005;6:635–645.
46. Andresen C, Helander S, Lemak A, et al. Transient structure and dynamics in the disordered c-Myc transactivation domain affect Bin1 binding. Nucleic Acids Res. 2012;40:6353–6366.
47. Sakamuro D, Prendergast GC. New Myc-interacting proteins: a second Myc network emerges. Oncogene. 1999;18:2942–2954.
48. Gianni S, Morrone A, Giri R, Brunori M. A folding-after-binding mechanism describes the recognition between the transactivation domain of c-Myb and the KIX domain of the CREB-binding protein. Biochem Biophys Res Commun. 2012;428:205–209.
49. Vacic V, Iakoucheva LM. Disease mutations in disordered regions – exception to the rule? Mol Biosyst. 2012;8:27–32.
50. Bahram F, von der Lehr N, Cetinkaya C, Larsson LG. c-Myc hot spot mutations in lymphomas result in inefficient ubiquitination and decreased proteasome-mediated turnover. Blood. 2000;95:2104–2110.
51. Chang DW, Claassen GF, Hann SR, Cole MD. The c-Myc transactivation domain is a direct modulator of apoptotic versus proliferative signals. Mol Cell Biol. 2000;20:4309–4319.
52. Uversky VN. Intrinsically disordered proteins and novel strategies for drug discovery. Expert Opin Drug Discov. 2012;7:475–488.
53. Robertson JG. Mechanistic basis of enzyme-targeted drugs. Biochemistry. 2005;44:5561–5571.
54. Clackson T, Wells JA. A hot spot of binding energy in a hormone-receptor interface. Science. 1995;267:383–386.
55. Metallo SJ. Intrinsically disordered proteins are potential drug targets. Curr Opin Chem Biol. 2010;14:481–488.
56. Vacic V, Oldfield CJ, Mohan A, et al. Characterization of molecular recognition features, MoRFs, and their binding partners. J Proteome Res. 2007;6:2351–2366.
57. Hammoudeh DI, Follis AV, Prochownik EV, Metallo SJ. Multiple independent binding sites for small-molecule inhibitors on the oncoprotein c-Myc. J Am Chem Soc. 2009;131:7390–7401.
58. Jin F, et al. Ligand Clouds around Protein Clouds: A Scenario of Ligand Binding with Intrinsically Disordered Proteins. PLoS Comput. Biol. 2013;9:e1003249.
59. Follis AV, Hammoudeh DI, Wang H, Prochownik EV, Metallo SJ. Structural rationale for the coupled binding and unfolding of the c-Myc oncoprotein by small molecules. Chem Biol. 2008;15:1149–1155.
60. Jin F, Yu C, Lai L, et al. Ligand clouds around protein clouds: a scenario of ligand binding with intrinsically disordered proteins. PLoS Comput Biol. 2013;9:e1003249.
61. Yu C, Niu X, Jin F, Liu Z, Jin C, Lai L. Structure-based inhibitor design for the intrinsically disordered protein c-Myc. Sci Rep. 2016;6:22298.
62. Jung K-Y, Wang H, Teriete P, et al. Perturbation of the c-Myc-Max proteinprotein interaction via synthetic α-helix mimetics. J Med Chem. 2015;58: 3002–3024.